Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 6/20 | 0.71 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543005 | 0.87 | CTSL (0.71) | METAP1CTSLCTSBALDH1A1MAPT | |
| SCHEMBL14712875 | 0.84 | METAP1 (0.71) | METAP1ALDH1A1RAB9AF2MAPT | |
| SCHEMBL13848519 | 0.83 | METAP1 (1.00) | METAP1ALDH1A1RAB9AF2MAPT | |
| SCHEMBL4044276 | 0.83 | METAP1 (1.00) | METAP1ALDH1A1RAB9AF2MAPT | |
| SCHEMBL14713019 | 0.82 | METAP1 (0.68) | METAP1CTSLCTSBALDH1A1RAB9A | |
| SCHEMBL14712871 | 0.80 | METAP1 (0.66) | METAP1CTSLCTSBALDH1A1RAB9A | |
| SCHEMBL14713027 | 0.80 | MAPT (0.77) | METAP1CTSLCTSBALDH1A1RAB9A | |
| SCHEMBL8026269 | 0.80 | METAP1 (1.00) | METAP1ALDH1A1RAB9AF2MAPT | |
| SCHEMBL30020331 | 0.80 | METAP1 (1.00) | METAP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14713065 | 0.76 | MAPT (0.55) | METAP1CTSLCTSBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| WO-2013024447-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | METAP1 2044/4885CTSL 4618/4885CTSB 3065/4885 |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAK1 | METAP1 2416/4885CTSL 3974/4885CTSB 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.